You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVoriconazole
Accession NumberDB00582  (APRD00543)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionVoriconazole (Vfend®, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections.
Structure
Thumb
Synonyms
(AlphaR,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
(R-(R*,s*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
VCZ
Vfend
Voriconazol
Voriconazolum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-voriconazoletablet50 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Auro-voriconazoletablet50 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-voriconazoletablet200 mgoralAuro Pharma IncNot applicableNot applicableCanada
Mylan-voriconazoletablet50 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-voriconazoletablet200 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Sandoz Voriconazoletablet50 mgoralSandoz Canada Incorporated2014-04-02Not applicableCanada
Sandoz Voriconazoletablet200 mgoralSandoz Canada Incorporated2014-04-02Not applicableCanada
Teva-voriconazoletablet50 mgoralTeva Canada Limited2014-03-31Not applicableCanada
Teva-voriconazoletablet200 mgoralTeva Canada Limited2014-03-31Not applicableCanada
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
Vfendtablet200 mgoralPfizer Canada Inc2004-11-12Not applicableCanada
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
Vfendpowder, for suspension40 mg/mLoralRoerig2003-03-28Not applicableUs
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
Vfendtablet, film coated200 mg/1oralCardinal Health2002-05-24Not applicableUs
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendPowder for solution for infusion200 mgIntravenous usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
Vfendtablet, film coated50 mg/1oralRoerig2003-03-28Not applicableUs
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendPowder for oral suspension40 mg/mlOral usePfizer Limited2002-03-19Not applicableEu
Vfendtablet, film coated50 mg/1oralCardinal Health2002-05-24Not applicableUs
Vfendpowder for suspension3 goralPfizer Canada Inc2008-07-17Not applicableCanada
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
Vfendtablet, film coated200 mg/1oralRoerig2003-03-28Not applicableUs
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendPowder and solvent for solution for infusion200 mgIntravenous usePfizer Limited2002-03-19Not applicableEu
Vfendtablet50 mgoralPfizer Canada Inc2004-11-12Not applicableCanada
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
Vfendinjection, powder, lyophilized, for solution10 mg/mLintravenousRoerig2012-10-24Not applicableUs
Vfendinjection, powder, lyophilized, for solution10 mg/mLintravenousRoerig2002-05-24Not applicableUs
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet50 mgOral usePfizer Limited2002-03-19Not applicableEu
VfendTablet200 mgOral usePfizer Limited2002-03-19Not applicableEu
Vfend for Injectionpowder for solution200 mgintravenousPfizer Canada Inc2004-11-12Not applicableCanada
Voriconazoletablet, film coated50 mg/1oralGreenstone LLC2002-05-01Not applicableUs
Voriconazoletablet, film coated200 mg/1oralGreenstone LLC2002-05-01Not applicableUs
Voriconazolepowder, for suspension40 mg/mLoralGreenstone LLC2013-12-16Not applicableUs
Voriconazole for Injectionpowder for solution200 mgintravenousHospira Healthcare CorporationNot applicableNot applicableCanada
Voriconazole for Injectionpowder for solution200 mgintravenousSandoz Canada Incorporated2014-04-30Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-voriconazoletablet50 mgoralApotex Inc2014-04-14Not applicableCanada
Apo-voriconazoletablet200 mgoralApotex Inc2014-04-14Not applicableCanada
Voriconazoletablet, film coated200 mg/1oralSandoz Inc2011-12-12Not applicableUs
Voriconazoletablet, film coated50 mg/1oralTeva Pharmaceuticals USA Inc2012-06-01Not applicableUs
Voriconazoletablet, film coated50 mg/1oralGlenmark Pharmaceuticals Inc., Usa2015-09-04Not applicableUs
Voriconazoletablet, film coated200 mg/1oralCardinal Health2012-09-21Not applicableUs
Voriconazolepowder, for suspension40 mg/mLoralMylan Pharmaceuticals Inc.2013-09-25Not applicableUs
Voriconazoletablet, film coated50 mg/1oralAurobindo Pharma Limited2016-01-22Not applicableUs
Voriconazoletablet, film coated200 mg/1oralMajor Pharmaceuticals2015-03-25Not applicableUs
Voriconazoletablet, film coated200 mg/1oralTeva Pharmaceuticals USA Inc2012-06-01Not applicableUs
Voriconazoletablet, film coated200 mg/1oralGlenmark Pharmaceuticals Inc., Usa2015-09-04Not applicableUs
Voriconazoletablet, film coated200 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-12-12Not applicableUs
Voriconazoletablet, film coated200 mg/1oralAurobindo Pharma Limited2016-01-22Not applicableUs
Voriconazoleinjection, powder, lyophilized, for solution10 mg/mLintravenousSandoz Inc2012-05-30Not applicableUs
Voriconazoletablet, film coated50 mg/1oralMylan Institutional Inc.2011-08-08Not applicableUs
Voriconazoletablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2011-02-15Not applicableUs
Voriconazoletablet, film coated200 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Voriconazoletablet, film coated50 mg/1oralSandoz Inc2011-12-12Not applicableUs
Voriconazoletablet, film coated200 mg/1oralAv Kare, Inc.2016-02-25Not applicableUs
Voriconazoletablet, film coated200 mg/1oralMylan Institutional Inc.2011-08-08Not applicableUs
Voriconazoletablet, film coated200 mg/1oralMylan Pharmaceuticals Inc.2011-02-15Not applicableUs
Voriconazoletablet, film coated50 mg/1oralAmerican Health Packaging2014-01-07Not applicableUs
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet200 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Voriconazole AccordFilm-coated tablet50 mgOral useAccord Healthcare Ltd2013-05-16Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIJFU09I87TR
CAS number137234-62-9
WeightAverage: 349.3105
Monoisotopic: 349.11504471
Chemical FormulaC16H14F3N5O
InChI KeyInChIKey=BCEHBSKCWLPMDN-MGPLVRAMSA-N
InChI
InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
IUPAC Name
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
SMILES
C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenylpropane
  • Halopyrimidine
  • Halobenzene
  • Fluorobenzene
  • Pyrimidine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Tertiary alcohol
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
PharmacodynamicsVoriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth.
Mechanism of actionVoriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a depletion of ergosterol in fungal cell membrane.
Related Articles
AbsorptionThe oral bioavailability is estimated to be 96% (CV 13%).
Volume of distribution
  • 4.6 L/kg
Protein binding58%
Metabolism

Hepatic. The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. Since this metabolite has minimal antifungal activity, it does not contribute to the overall efficacy of voriconazole.

SubstrateEnzymesProduct
Voriconazole
UK-121,265 (Voriconazole N-oxide)Details
Voriconazole
4-HydroxyvoriconazoleDetails
4-Hydroxyvoriconazole
Not Available
4-Hydroxyvoriconazole 4-O-glucuronideDetails
UK-121,265 (Voriconazole N-oxide)
Not Available
UK-51,060Details
UK-51,060
Not Available
UK-215,364Details
UK-215,364
Not Available
Voriconazole O-glucuronide derivative (1)Details
Route of eliminationVoriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicityThe minimum lethal oral dose in mice and rats was 300 mg/kg (equivalent to 4 and 7 times the recommended maintenance dose (RMD), based on body surface area). At this dose, clinical signs observed in both mice and rats included salivation, mydriasis, titubation (loss of balance while moving), depressed behavior, prostration, partially closed eyes, and dyspnea. Other signs in mice were convulsions, corneal opacification and swollen abdomen.
Affected organisms
  • Yeast and other fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9047
Caco-2 permeable+0.7219
P-glycoprotein substrateSubstrate0.591
P-glycoprotein inhibitor INon-inhibitor0.6113
P-glycoprotein inhibitor IINon-inhibitor0.8195
Renal organic cation transporterNon-inhibitor0.5354
CYP450 2C9 substrateNon-substrate0.727
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5792
CYP450 1A2 substrateNon-inhibitor0.7491
CYP450 2C9 inhibitorInhibitor0.5203
CYP450 2D6 inhibitorNon-inhibitor0.8315
CYP450 2C19 inhibitorInhibitor0.5784
CYP450 3A4 inhibitorNon-inhibitor0.7011
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6649
Ames testNon AMES toxic0.7019
CarcinogenicityNon-carcinogens0.776
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3469 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8791
hERG inhibition (predictor II)Non-inhibitor0.6282
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous10 mg/mL
Powder and solvent for solution for infusionIntravenous use200 mg
Powder for oral suspensionOral use40 mg/ml
Powder for solution for infusionIntravenous use200 mg
Powder for suspensionoral3 g
Powder, for suspensionoral40 mg/mL
Tabletoral200 mg
Tabletoral50 mg
TabletOral use200 mg
TabletOral use50 mg
Tablet, film coatedoral200 mg/1
Tablet, film coatedoral50 mg/1
Powder for solutionintravenous200 mg
Film-coated tabletOral use200 mg
Film-coated tabletOral use50 mg
Prices
Unit descriptionCostUnit
Vfend 40 mg/ml Suspension 75ml Bottle870.72USD bottle
Vfend iv 200 mg vial143.5USD vial
Vfend 200 mg tablet49.74USD tablet
Vfend 50 mg tablet12.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2035314 No2000-01-182011-01-30Canada
CA2295035 No2005-04-192018-06-02Canada
US5116844 No1992-08-112009-08-11Us
US5567817 No1996-05-242016-05-24Us
US6632803 No1998-06-022018-06-02Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point127-130 °CNot Available
water solubilityLowNot Available
logP1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0978 mg/mLALOGPS
logP1.65ALOGPS
logP1.82ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.71ChemAxon
pKa (Strongest Basic)2.27ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area76.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity95.28 m3·mol-1ChemAxon
Polarizability30.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Venkataraman Sundaram, Venkata Bhaskara Rao Uppala, Surya Prabhakar Akundi, Venkateswarlu Muvva, Vijayawardhan Chitta, Alekhya Donthula, Manoj Ramesh Kharkar, Surya Narayana Devarakonda, Subba Reddy Peddireddy, “Process For Preparing Voriconazole.” U.S. Patent US20080194820, issued August 14, 2008.

US20080194820
General References
  1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408-15. [PubMed:12167683 ]
  2. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis. 2005 Nov 15;41(10):1448-52. Epub 2005 Oct 13. [PubMed:16231256 ]
  3. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005 Oct 22-28;366(9495):1435-42. [PubMed:16243088 ]
  4. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001 Nov 1;33(9):1447-54. Epub 2001 Sep 26. [PubMed:11577374 ]
  5. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002 Jan 24;346(4):225-34. [PubMed:11807146 ]
External Links
ATC CodesJ02AC03
AHFS Codes
  • 08:14.08
PDB EntriesNot Available
FDA labelDownload (321 KB)
MSDSDownload (57.2 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Voriconazole.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Voriconazole.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Voriconazole.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Voriconazole.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Voriconazole.
AcetohexamideThe serum concentration of Acetohexamide can be increased when it is combined with Voriconazole.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Voriconazole.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Voriconazole.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Voriconazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Voriconazole.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Voriconazole.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Voriconazole.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Voriconazole.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Voriconazole.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Voriconazole.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Voriconazole.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Voriconazole.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Voriconazole.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Voriconazole.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Voriconazole.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Voriconazole.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Voriconazole.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Voriconazole.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Voriconazole.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Voriconazole.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Voriconazole.
AmlodipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Amlodipine.
AmobarbitalThe serum concentration of Voriconazole can be decreased when it is combined with Amobarbital.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Voriconazole.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Voriconazole.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Voriconazole.
AmrinoneThe risk or severity of adverse effects can be increased when Voriconazole is combined with Amrinone.
AnagrelideVoriconazole may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Voriconazole.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Voriconazole.
ApremilastThe metabolism of Apremilast can be decreased when combined with Voriconazole.
AprepitantThe serum concentration of Voriconazole can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Voriconazole.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Voriconazole.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Voriconazole.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Voriconazole.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Voriconazole.
ArmodafinilThe metabolism of Voriconazole can be decreased when combined with Armodafinil.
Arsenic trioxideVoriconazole may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe metabolism of Artemether can be decreased when combined with Voriconazole.
AsenapineThe metabolism of Asenapine can be decreased when combined with Voriconazole.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Voriconazole.
AtazanavirThe serum concentration of Voriconazole can be decreased when it is combined with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Voriconazole.
AtomoxetineThe metabolism of Voriconazole can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Voriconazole.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Voriconazole.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Voriconazole.
AzelastineThe metabolism of Azelastine can be decreased when combined with Voriconazole.
AzelnidipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Azelnidipine.
AzimilideThe risk or severity of adverse effects can be increased when Voriconazole is combined with Azimilide.
AzithromycinVoriconazole may increase the QTc-prolonging activities of Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Voriconazole.
BarbitalThe serum concentration of Voriconazole can be decreased when it is combined with Barbital.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Voriconazole.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Voriconazole.
BedaquilineVoriconazole may increase the QTc-prolonging activities of Bedaquiline.
BenidipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Benidipine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Voriconazole.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Voriconazole.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Voriconazole.
BepridilThe risk or severity of adverse effects can be increased when Voriconazole is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Voriconazole.
BexaroteneThe serum concentration of Voriconazole can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Voriconazole.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Voriconazole.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Voriconazole.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Voriconazole.
BoceprevirThe serum concentration of Voriconazole can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Voriconazole.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Voriconazole.
BortezomibThe metabolism of Voriconazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Voriconazole can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Voriconazole.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Voriconazole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Voriconazole.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Voriconazole.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Voriconazole.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Voriconazole.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Voriconazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Voriconazole.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Voriconazole.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Voriconazole.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Voriconazole.
BupropionThe metabolism of Bupropion can be decreased when combined with Voriconazole.
BuspironeThe metabolism of Buspirone can be decreased when combined with Voriconazole.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Voriconazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Voriconazole.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Voriconazole.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Voriconazole.
CaffeineThe metabolism of Caffeine can be decreased when combined with Voriconazole.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Voriconazole.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Voriconazole.
CandesartanThe metabolism of Candesartan can be decreased when combined with Voriconazole.
CapecitabineThe metabolism of Voriconazole can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of Voriconazole can be decreased when it is combined with Carbamazepine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Voriconazole.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Voriconazole.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Voriconazole.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Voriconazole.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Voriconazole.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Voriconazole.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Voriconazole.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Voriconazole.
CeritinibThe serum concentration of Voriconazole can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Voriconazole.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Voriconazole.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Voriconazole.
ChloramphenicolThe serum concentration of Voriconazole can be increased when it is combined with Chloramphenicol.
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Voriconazole.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Voriconazole.
ChloroquineVoriconazole may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Voriconazole.
ChlorpromazineVoriconazole may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Voriconazole.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Voriconazole.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Voriconazole.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Voriconazole.
CilnidipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Cilnidipine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Voriconazole.
CimetidineThe metabolism of Voriconazole can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Voriconazole.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Voriconazole.
CiprofloxacinVoriconazole may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Voriconazole.
CitalopramThe metabolism of Voriconazole can be decreased when combined with Citalopram.
ClarithromycinVoriconazole may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Voriconazole can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Voriconazole can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Voriconazole.
ClobazamThe metabolism of Clobazam can be decreased when combined with Voriconazole.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Voriconazole.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Voriconazole.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Voriconazole.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Voriconazole.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Voriconazole.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Voriconazole.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Voriconazole.
ClonidineThe metabolism of Clonidine can be decreased when combined with Voriconazole.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Voriconazole.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Voriconazole.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Voriconazole.
ClotrimazoleThe metabolism of Voriconazole can be decreased when combined with Clotrimazole.
ClozapineVoriconazole may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Cobicistat can be increased when it is combined with Voriconazole.
CobicistatThe metabolism of Voriconazole can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Voriconazole.
CocaineThe metabolism of Cocaine can be decreased when combined with Voriconazole.
CodeineThe metabolism of Codeine can be decreased when combined with Voriconazole.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Voriconazole.
ConivaptanThe serum concentration of Voriconazole can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Voriconazole.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Voriconazole.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Voriconazole.
CrizotinibThe metabolism of Voriconazole can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Voriconazole.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Voriconazole.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Voriconazole.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Voriconazole.
DabrafenibThe serum concentration of Voriconazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Voriconazole.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Voriconazole.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Voriconazole.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Voriconazole.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Voriconazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Voriconazole.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Voriconazole.
DarodipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Darodipine.
DarunavirThe serum concentration of Voriconazole can be decreased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Voriconazole.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Voriconazole.
DasatinibThe serum concentration of Voriconazole can be increased when it is combined with Dasatinib.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Voriconazole.
DeferasiroxThe serum concentration of Voriconazole can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Voriconazole.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Voriconazole.
DelavirdineThe metabolism of Voriconazole can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Voriconazole.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Voriconazole.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Voriconazole.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Voriconazole.
DexamethasoneThe serum concentration of Voriconazole can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Voriconazole.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Voriconazole.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Voriconazole.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Voriconazole.
DiazepamThe metabolism of Diazepam can be decreased when combined with Voriconazole.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Voriconazole.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Voriconazole.
DidanosineDidanosine can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Voriconazole.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Voriconazole.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Voriconazole.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Voriconazole.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Voriconazole.
DigoxinThe metabolism of Digoxin can be decreased when combined with Voriconazole.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Voriconazole.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Voriconazole.
DihydroergotamineThe metabolism of Voriconazole can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Voriconazole can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Voriconazole.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Voriconazole.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Voriconazole.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Voriconazole.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Voriconazole.
DolasetronVoriconazole may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Voriconazole.
DonepezilThe metabolism of Donepezil can be decreased when combined with Voriconazole.
DopamineThe metabolism of Dopamine can be decreased when combined with Voriconazole.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Voriconazole.
DotarizineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Dotarizine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Voriconazole.
DoxepinThe metabolism of Doxepin can be decreased when combined with Voriconazole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Voriconazole.
DoxycyclineThe metabolism of Voriconazole can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Voriconazole.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Voriconazole.
DronedaroneThe metabolism of Voriconazole can be decreased when combined with Dronedarone.
DroperidolVoriconazole may increase the QTc-prolonging activities of Droperidol.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Voriconazole.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Voriconazole.
EfavirenzThe serum concentration of Voriconazole can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Voriconazole.
EfonidipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Voriconazole.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Voriconazole.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Voriconazole.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Voriconazole.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Voriconazole.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Voriconazole.
EnzalutamideThe serum concentration of Voriconazole can be decreased when it is combined with Enzalutamide.
EperisoneThe risk or severity of adverse effects can be increased when Voriconazole is combined with Eperisone.
EpinastineThe metabolism of Epinastine can be decreased when combined with Voriconazole.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Voriconazole.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Voriconazole.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Voriconazole.
EquilinThe serum concentration of Equilin can be increased when it is combined with Voriconazole.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Voriconazole.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Voriconazole.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Voriconazole.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Voriconazole.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Voriconazole.
ErythromycinVoriconazole may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Voriconazole can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Voriconazole.
Eslicarbazepine acetateThe serum concentration of Voriconazole can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Voriconazole.
EsomeprazoleThe metabolism of Voriconazole can be decreased when combined with Esomeprazole.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Voriconazole.
EstradiolThe metabolism of Estradiol can be decreased when combined with Voriconazole.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Voriconazole.
EstramustineThe metabolism of Estramustine can be decreased when combined with Voriconazole.
EstroneThe metabolism of Estrone can be decreased when combined with Voriconazole.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Voriconazole.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Voriconazole.
EthanolThe metabolism of Ethanol can be decreased when combined with Voriconazole.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Voriconazole.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Voriconazole.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Voriconazole.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Voriconazole.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Voriconazole.
EtodolacThe metabolism of Etodolac can be decreased when combined with Voriconazole.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Voriconazole.
EtoposideThe metabolism of Etoposide can be decreased when combined with Voriconazole.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Voriconazole.
EtravirineThe serum concentration of Voriconazole can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Voriconazole.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Voriconazole.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Voriconazole.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Voriconazole.
FamotidineThe metabolism of Famotidine can be decreased when combined with Voriconazole.
FelbamateThe metabolism of Felbamate can be decreased when combined with Voriconazole.
FelodipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Felodipine.
FendilineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Fendiline.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Voriconazole.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Voriconazole.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Voriconazole.
FinasterideThe metabolism of Finasteride can be decreased when combined with Voriconazole.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Voriconazole.
FlecainideVoriconazole may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Voriconazole.
FloxuridineThe metabolism of Voriconazole can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Voriconazole can be increased when it is combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Voriconazole.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Voriconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Voriconazole.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Voriconazole.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Voriconazole.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Voriconazole.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Voriconazole.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Voriconazole.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Voriconazole.
FluorouracilThe metabolism of Voriconazole can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Voriconazole can be decreased when combined with Fluoxetine.
FlupentixolVoriconazole may increase the QTc-prolonging activities of Flupentixol.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Voriconazole.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Voriconazole.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Voriconazole.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Voriconazole.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Voriconazole.
FlutamideThe metabolism of Flutamide can be decreased when combined with Voriconazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Voriconazole.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Voriconazole.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Voriconazole.
FluvoxamineThe metabolism of Voriconazole can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Voriconazole.
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be increased when Fosamprenavir is used in combination with Voriconazole.
FosamprenavirThe metabolism of Voriconazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Voriconazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Voriconazole can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Voriconazole.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Voriconazole.
Fusidic AcidThe serum concentration of Voriconazole can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Voriconazole is combined with Gabapentin.
Gadobenic acidVoriconazole may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Voriconazole.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Voriconazole.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Voriconazole.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Voriconazole.
GemifloxacinVoriconazole may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideThe serum concentration of Glibornuride can be increased when it is combined with Voriconazole.
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Voriconazole.
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Voriconazole.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Voriconazole.
GliquidoneThe serum concentration of Gliquidone can be increased when it is combined with Voriconazole.
GlisoxepideThe serum concentration of Glisoxepide can be increased when it is combined with Voriconazole.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Voriconazole.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Voriconazole.
GoserelinVoriconazole may increase the QTc-prolonging activities of Goserelin.
GranisetronVoriconazole may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Voriconazole.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Voriconazole.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Voriconazole.
HaloperidolVoriconazole may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Voriconazole.
HexobarbitalThe serum concentration of Voriconazole can be decreased when it is combined with Hexobarbital.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Voriconazole.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Voriconazole.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Voriconazole.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Voriconazole.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Voriconazole.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Voriconazole.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Voriconazole.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Voriconazole.
IbutilideVoriconazole may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Voriconazole.
IdelalisibThe serum concentration of Voriconazole can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Voriconazole resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Voriconazole.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Voriconazole.
ImatinibThe metabolism of Voriconazole can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Voriconazole.
ImipramineThe metabolism of Imipramine can be decreased when combined with Voriconazole.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Voriconazole.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Voriconazole.
IndapamideThe metabolism of Indapamide can be decreased when combined with Voriconazole.
IndinavirThe metabolism of Indinavir can be decreased when combined with Voriconazole.
indisulamThe metabolism of indisulam can be decreased when combined with Voriconazole.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Voriconazole.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Voriconazole.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Voriconazole.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Voriconazole.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Voriconazole.
IsavuconazoniumThe metabolism of Voriconazole can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Voriconazole can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Voriconazole.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Voriconazole.
IsradipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Isradipine.
IsradipineThe metabolism of Voriconazole can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Voriconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Voriconazole.
IvacaftorThe serum concentration of Voriconazole can be increased when it is combined with Ivacaftor.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Voriconazole.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Voriconazole.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Voriconazole.
KetamineThe metabolism of Ketamine can be decreased when combined with Voriconazole.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Voriconazole.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Voriconazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Voriconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Voriconazole.
LacidipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Lacidipine.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Voriconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Lamotrigine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Voriconazole.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Voriconazole.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Voriconazole.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Voriconazole.
LenvatinibVoriconazole may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Voriconazole.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Voriconazole.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Voriconazole.
LeuprolideVoriconazole may increase the QTc-prolonging activities of Leuprolide.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Voriconazole.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Voriconazole.
LevofloxacinVoriconazole may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Voriconazole.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Voriconazole.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Voriconazole.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Voriconazole.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Voriconazole.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Voriconazole.
LisurideThe metabolism of Lisuride can be decreased when combined with Voriconazole.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Voriconazole.
LoperamideThe metabolism of Loperamide can be decreased when combined with Voriconazole.
LopinavirThe serum concentration of Voriconazole can be decreased when it is combined with Lopinavir.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Voriconazole.
LoratadineThe metabolism of Loratadine can be decreased when combined with Voriconazole.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Voriconazole.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Voriconazole.
LosartanThe metabolism of Losartan can be decreased when combined with Voriconazole.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Voriconazole.
LovastatinThe metabolism of Voriconazole can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Voriconazole can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Voriconazole can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Voriconazole.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Voriconazole.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Voriconazole.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Voriconazole.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Voriconazole is combined with Magnesium Sulfate.
ManidipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Manidipine.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Voriconazole.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Voriconazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Voriconazole.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Voriconazole.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Voriconazole.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Voriconazole.
MelatoninThe metabolism of Melatonin can be decreased when combined with Voriconazole.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Voriconazole.
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Voriconazole.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Voriconazole.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Voriconazole.
MestranolThe metabolism of Mestranol can be decreased when combined with Voriconazole.
MethadoneVoriconazole may increase the QTc-prolonging activities of Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Voriconazole.
MethohexitalThe serum concentration of Voriconazole can be decreased when it is combined with Methohexital.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Voriconazole.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Voriconazole.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Voriconazole.
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Voriconazole.
MethylphenobarbitalThe serum concentration of Voriconazole can be decreased when it is combined with Methylphenobarbital.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Voriconazole.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Voriconazole.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Voriconazole.
MetoprololThe metabolism of Metoprolol can be decreased when combined with Voriconazole.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Voriconazole.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Voriconazole.
MianserinThe metabolism of Mianserin can be decreased when combined with Voriconazole.
MibefradilThe risk or severity of adverse effects can be increased when Voriconazole is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Voriconazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Voriconazole.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Voriconazole.
MifepristoneThe metabolism of Voriconazole can be decreased when combined with Mifepristone.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Voriconazole.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Voriconazole.
MitotaneThe serum concentration of Voriconazole can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Voriconazole.
ModafinilThe serum concentration of Voriconazole can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Voriconazole.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Voriconazole.
MontelukastThe metabolism of Montelukast can be decreased when combined with Voriconazole.
MorphineThe metabolism of Morphine can be decreased when combined with Voriconazole.
MoxifloxacinVoriconazole may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Voriconazole.
NafcillinThe serum concentration of Voriconazole can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Voriconazole.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Voriconazole.
NaproxenThe metabolism of Naproxen can be decreased when combined with Voriconazole.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Voriconazole.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Voriconazole.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Voriconazole.
NelfinavirThe metabolism of Voriconazole can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Voriconazole can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Voriconazole.
NevirapineThe metabolism of Voriconazole can be decreased when combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nicardipine.
NicardipineThe metabolism of Voriconazole can be decreased when combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Voriconazole.
NicotineThe metabolism of Nicotine can be decreased when combined with Voriconazole.
NifedipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nifedipine.
NiguldipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Voriconazole.
NilotinibThe metabolism of Voriconazole can be decreased when combined with Nilotinib.
NiludipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Niludipine.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Voriconazole.
NilvadipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nimesulide.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Voriconazole.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Voriconazole.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Voriconazole.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Voriconazole.
NitrendipineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nitrendipine.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Voriconazole.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Voriconazole.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Voriconazole.
OfloxacinVoriconazole may increase the QTc-prolonging activities of Ofloxacin.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Voriconazole.
OlaparibThe metabolism of Voriconazole can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Voriconazole.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Voriconazole.
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Voriconazole.
OmeprazoleThe metabolism of Voriconazole can be decreased when combined with Omeprazole.
OndansetronVoriconazole may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Voriconazole.
OsimertinibThe serum concentration of Voriconazole can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Voriconazole.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Voriconazole.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Voriconazole.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Voriconazole.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Voriconazole.
OxycodoneThe risk or severity of adverse effects can be increased when Voriconazole is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Voriconazole.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Voriconazole.
PalbociclibThe serum concentration of Voriconazole can be increased when it is combined with Palbociclib.
PaliperidoneVoriconazole may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Voriconazole.
PanobinostatVoriconazole may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Voriconazole.
PantoprazoleThe metabolism of Voriconazole can be decreased when combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Voriconazole.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Voriconazole.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Voriconazole.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Voriconazole.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Voriconazole.
PazopanibVoriconazole may increase the QTc-prolonging activities of Pazopanib.
PentamidineVoriconazole may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe serum concentration of Voriconazole can be decreased when it is combined with Pentobarbital.
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Voriconazole.
PerampanelThe metabolism of Perampanel can be decreased when combined with Voriconazole.
PerflutrenVoriconazole may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Voriconazole.
PerhexilineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Perhexiline.
PermethrinThe metabolism of Permethrin can be decreased when combined with Voriconazole.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Voriconazole.
PethidineThe metabolism of Pethidine can be decreased when combined with Voriconazole.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Voriconazole.
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Voriconazole.
PhenobarbitalThe serum concentration of Voriconazole can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Voriconazole.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Voriconazole.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Voriconazole.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Voriconazole.
PhenytoinThe metabolism of Voriconazole can be increased when combined with Phenytoin.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Voriconazole.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Voriconazole.
PimozideVoriconazole may increase the arrhythmogenic activities of Pimozide.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Voriconazole.
PinaveriumThe risk or severity of adverse effects can be increased when Voriconazole is combined with Pinaverium.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Voriconazole.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Voriconazole.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Voriconazole.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Voriconazole.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Voriconazole.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Voriconazole.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Voriconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Voriconazole.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Voriconazole.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Voriconazole resulting in a loss in efficacy.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Voriconazole.
PrazepamThe metabolism of Prazepam can be decreased when combined with Voriconazole.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Voriconazole.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Voriconazole.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Voriconazole.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Voriconazole.
PregabalinThe risk or severity of adverse effects can be increased when Voriconazole is combined with Pregabalin.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Voriconazole.
PrenylamineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Prenylamine.
PrimaquineVoriconazole may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Voriconazole can be decreased when it is combined with Primidone.
PrimidoneThe metabolism of Primidone can be decreased when combined with Voriconazole.
ProcainamideVoriconazole may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Voriconazole.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Voriconazole.
ProguanilThe metabolism of Proguanil can be decreased when combined with Voriconazole.
PromazineVoriconazole may increase the QTc-prolonging activities of Promazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Voriconazole.
PropofolThe metabolism of Propofol can be decreased when combined with Voriconazole.
PropranololThe metabolism of Propranolol can be decreased when combined with Voriconazole.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Voriconazole.
PyrimethamineThe metabolism of Voriconazole can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Voriconazole.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Voriconazole.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Voriconazole.
QuinidineThe metabolism of Quinidine can be decreased when combined with Voriconazole.
QuinineThe metabolism of Quinine can be decreased when combined with Voriconazole.
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Voriconazole.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Voriconazole.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Voriconazole.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Voriconazole.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Voriconazole.
RanolazineThe metabolism of Voriconazole can be decreased when combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Voriconazole.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Voriconazole.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Voriconazole.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Voriconazole.
RifabutinThe metabolism of Voriconazole can be increased when combined with Rifabutin.
RifampicinThe metabolism of Voriconazole can be increased when combined with Rifampicin.
RifapentineThe metabolism of Voriconazole can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Voriconazole.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Voriconazole.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Voriconazole.
RiociguatThe metabolism of Riociguat can be decreased when combined with Voriconazole.
RisedronateThe risk or severity of adverse effects can be increased when Voriconazole is combined with Risedronate.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Voriconazole.
RitonavirThe serum concentration of Voriconazole can be decreased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Voriconazole.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Voriconazole.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Voriconazole.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Voriconazole.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Voriconazole.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Voriconazole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Voriconazole.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Voriconazole.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Voriconazole.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Voriconazole.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Voriconazole.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Voriconazole.
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Voriconazole.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Voriconazole.
SaquinavirVoriconazole may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Voriconazole can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Voriconazole.
SecobarbitalThe serum concentration of Voriconazole can be decreased when it is combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Voriconazole.
SelexipagThe metabolism of Selexipag can be decreased when combined with Voriconazole.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Voriconazole.
SertindoleThe metabolism of Sertindole can be decreased when combined with Voriconazole.
SertralineThe metabolism of Sertraline can be decreased when combined with Voriconazole.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Voriconazole.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Voriconazole.
SildenafilThe metabolism of Voriconazole can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Voriconazole.
SiltuximabThe serum concentration of Voriconazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Voriconazole can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Voriconazole.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Voriconazole.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Voriconazole.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Voriconazole.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Voriconazole.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Voriconazole.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Voriconazole.
SorafenibThe metabolism of Voriconazole can be decreased when combined with Sorafenib.
SotalolVoriconazole may increase the QTc-prolonging activities of Sotalol.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Voriconazole.
St. John's WortThe serum concentration of Voriconazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Voriconazole can be increased when it is combined with Stiripentol.
SucralfateSucralfate can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Voriconazole.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Voriconazole.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Voriconazole.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Voriconazole.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Voriconazole.
SulfisoxazoleVoriconazole may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Voriconazole can be decreased when combined with Sulfisoxazole.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Voriconazole.
SuprofenThe metabolism of Suprofen can be decreased when combined with Voriconazole.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Voriconazole.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Voriconazole.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Voriconazole.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Voriconazole.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Voriconazole.
TAK-390MRThe serum concentration of TAK-390MR can be increased when it is combined with Voriconazole.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Voriconazole.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Voriconazole.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Voriconazole.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Voriconazole.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Voriconazole.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Voriconazole.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Voriconazole.
TelaprevirThe metabolism of Voriconazole can be decreased when combined with Telaprevir.
TelavancinVoriconazole may increase the QTc-prolonging activities of Telavancin.
TelithromycinVoriconazole may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Voriconazole can be decreased when combined with Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Voriconazole.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Voriconazole.
TeniposideThe metabolism of Teniposide can be decreased when combined with Voriconazole.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Voriconazole.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Voriconazole.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Voriconazole.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Voriconazole.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Voriconazole.
TetrabenazineVoriconazole may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Voriconazole.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Voriconazole.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Voriconazole.
ThiamylalThe serum concentration of Voriconazole can be decreased when it is combined with Thiamylal.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Voriconazole.
ThiopentalThe serum concentration of Voriconazole can be decreased when it is combined with Thiopental.
ThioridazineThe metabolism of Thioridazine can be decreased when combined with Voriconazole.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Voriconazole.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Voriconazole.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Voriconazole resulting in a loss in efficacy.
TicagrelorThe metabolism of Voriconazole can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Voriconazole can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Voriconazole.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Voriconazole.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Voriconazole.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Voriconazole.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Voriconazole.
TocilizumabThe serum concentration of Voriconazole can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Voriconazole.
TolazamideThe serum concentration of Tolazamide can be increased when it is combined with Voriconazole.
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Voriconazole.
TolbutamideThe metabolism of Voriconazole can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Voriconazole is combined with Tolfenamic Acid.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Voriconazole.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Voriconazole.
TopiramateThe metabolism of Voriconazole can be decreased when combined with Topiramate.
TorasemideThe metabolism of Torasemide can be decreased when combined with Voriconazole.
ToremifeneThe risk or severity of adverse effects can be increased when Voriconazole is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Voriconazole.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Voriconazole.
TranilastThe risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast.
TranylcypromineThe metabolism of Voriconazole can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Voriconazole.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Voriconazole.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Voriconazole.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Voriconazole.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Voriconazole.
TriazolamThe metabolism of Triazolam can be decreased when combined with Voriconazole.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Voriconazole.
TrimethoprimThe metabolism of Voriconazole can be decreased when combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Voriconazole.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Voriconazole.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Voriconazole.
UdenafilThe metabolism of Udenafil can be decreased when combined with Voriconazole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Voriconazole.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Voriconazole.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Voriconazole.
ValsartanThe metabolism of Voriconazole can be decreased when combined with Valsartan.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Voriconazole.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Voriconazole.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Voriconazole.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Voriconazole.
VenlafaxineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Venlafaxine.
VenlafaxineThe metabolism of Voriconazole can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Voriconazole can be decreased when combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Voriconazole.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Voriconazole.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Voriconazole.
VinblastineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Voriconazole.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Voriconazole.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Voriconazole.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Voriconazole.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Voriconazole.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Voriconazole.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Voriconazole.
XylometazolineThe risk or severity of adverse effects can be increased when Voriconazole is combined with Xylometazoline.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Voriconazole.
ZafirlukastThe metabolism of Voriconazole can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Voriconazole.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Voriconazole.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Voriconazole.
ZiconotideThe risk or severity of adverse effects can be increased when Voriconazole is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Voriconazole.
ZileutonThe metabolism of Zileuton can be decreased when combined with Voriconazole.
ZiprasidoneThe metabolism of Voriconazole can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Voriconazole.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Voriconazole.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Voriconazole.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Voriconazole.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Voriconazole.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
yes
Actions
antagonistinhibitor
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name:
ERG11
Uniprot ID:
P10613
Molecular Weight:
60674.965 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr: Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol. 2003 Aug;29(2):232-8. Epub 2003 Feb 26. [PubMed:12606318 ]
  4. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G: Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005 Feb;49(2):668-79. [PubMed:15673750 ]
  5. Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM: Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4. [PubMed:14657086 ]
  6. Thompson GR 3rd, Lewis JS 2nd: Pharmacology and clinical use of voriconazole. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):83-94. doi: 10.1517/17425250903463878. [PubMed:19947892 ]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  8. Xu Y, Sheng C, Wang W, Che X, Cao Y, Dong G, Wang S, Ji H, Miao Z, Yao J, Zhang W: Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives. Bioorg Med Chem Lett. 2010 May 1;20(9):2942-5. doi: 10.1016/j.bmcl.2010.03.014. Epub 2010 Mar 7. [PubMed:20362444 ]
  9. Xu J, Cao Y, Zhang J, Yu S, Zou Y, Chai X, Wu Q, Zhang D, Jiang Y, Sun Q: Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives. Eur J Med Chem. 2011 Jul;46(7):3142-8. doi: 10.1016/j.ejmech.2011.02.042. Epub 2011 Feb 24. [PubMed:21420761 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nadp binding
Specific Function:
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name:
FMO1
Uniprot ID:
Q01740
Molecular Weight:
60310.285 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:13